Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider operating in India. The company is focused on delivering a high standard of patient care, guided by a "Patient First" philosophy as articulated by its leadership. It operates a chain of hospitals and is actively engaged in a significant expansion phase, particularly in the western region of India. The company's strategy involves both greenfield projects and potential expansions of existing facilities to increase its bed capacity and geographic footprint. Key operational metrics such as patient volumes, bed occupancy, and revenue per bed are closely tracked to measure performance. The company is demonstrating strong execution capabilities, evidenced by the ahead-of-schedule completion of major new hospital projects. This positions Jupiter Life Line Hospitals as a growth-oriented entity within the Indian healthcare sector, committed to scaling its operations to meet rising demand.

Official Website: http://www.jupiterhospital.com/

• Quarterly Performance (Q3FY26 vs Q3FY25)

• Total Income: Increased by 9.8% to Rs 365.3 crore from Rs 332.8 crore.

• EBITDA: Grew by 9.2% to Rs 83.4 crore from Rs 76.4 crore. The EBITDA figure for Q3FY26 was revised to Rs 85.4 crore for operational calculations (Slide 5), though the consolidated P&L lists Rs 83.4 crore.

• Profit Before Tax (PBT): Declined by 14.8% to Rs 56.9 crore from Rs 66.8 crore. This was primarily due to an exceptional item charge.

• Profit After Tax (PAT): Decreased by 18.7% to Rs 42.5 crore from Rs 52.3 crore.

• Exceptional Item: The company recorded an exceptional charge of Rs 6.4 crore related to the statutory impact of New Labour Codes, which directly impacted profitability for the quarter.

• Nine-Month Performance (9MFY26 vs 9MFY25)

• Total Income: Rose by 15.1% to Rs 1,111.9 crore from Rs 965.7 crore.

• EBITDA: Increased by 15.2% to Rs 254.0 crore from Rs 220.5 crore. The operational EBITDA figure for 9MFY26 was revised to Rs 249.2 crore (Slide 6).

• Profit Before Tax (PBT): Saw a slight decline of 2.3% to Rs 192.9 crore from Rs 197.4 crore, again influenced by the exceptional charge.

• Profit After Tax (PAT): Declined by 3.1% to Rs 143.9 crore from Rs 148.5 crore.

• Earnings Per Share (EPS): Basic EPS for 9MFY26 stood at 21.93, compared to 22.58 in 9MFY25.

The company demonstrated healthy top-line growth for the nine-month period, though profitability was constrained by a one-time exceptional charge related to regulatory changes.

• Revenue Growth

• Revenue from Operations for the nine months ended December 31, 2025 (9MFY26) grew by 15.3% year-over-year to Rs 1,063.8 crore.

• The growth was driven by increases across all segments: In-patient Department (IPD) revenue grew to Rs 852.1 crore, Out-patient Department (OPD) revenue grew to Rs 193.7 crore, and other revenue grew to Rs 48.1 crore.

• Operational Growth

• In-patient (IPD) Volume: The number of in-patients increased to 40,700 in 9MFY26 from 40,200 in the corresponding period of the previous year.

• Out-patient (OPD) Volume: OPD volumes showed strong growth, rising to 803,100 in 9MFY26 from 727,500 in 9MFY25.

• Average Revenue Per Occupied Bed (ARPOB): ARPOB improved to Rs 66,800 in 9MFY26 from Rs 59,000 in 9MFY25, indicating better revenue efficiency and case mix.

The company's growth is supported by a solid increase in patient volumes, particularly in the out-patient segment, and improved monetization per bed.

• Current Capacity & Utilization

• Operational Bed Capacity: The company's total operational bed capacity stands at 1,048 beds as of 9MFY26, an increase from 983 beds in 9MFY25.

• Average Occupancy Rate: The average occupancy rate for 9MFY26 was 61.9%. This is lower than the 67.5% recorded in 9MFY25, which is attributed to the recent expansion of bed capacity ahead of full ramp-up.

• Average Length of Stay (ALOS): ALOS remained stable at 3.85 days, indicating consistent operational efficiency in patient turnover.

• Capital Expenditure (Capex)

• Dombivli Hospital: The first phase of the Dombivli hospital was completed with a capex of approximately Rs 425 crore. This phase includes infrastructure for 500 beds, fit-outs for over 300 beds, and initial operationalization of 200 beds.

• Future Projects: The company has outlined significant capex for its next phase of growth, including an estimated Rs 500 crore for the Pune South hospital and Rs 300 crore for the Mira-Bhayandar hospital.

The company is in a significant investment cycle, expanding its physical infrastructure, which has temporarily lowered overall occupancy rates but is laying the groundwork for future revenue streams.

• Dombivli Hospital

• This new 500-bed hospital has been completed ahead of schedule and will be launched in phases.

• OPD services are set to begin in the first week of February 2026, with full clinical operations commencing on February 18, 2026.

• Initially, 200 beds will be made operational, with the remaining capacity to be scaled up as occupancy increases.

• Pune South (Bibwewadi) Hospital

• A new 500-bed hospital is planned for this location.

• The project is currently on the drawing board and is expected to be operational by the calendar year 2028.

• Mira-Bhayandar Hospital

• A new 300-bed hospital is planned for this region.

• Project execution is on track, with an expected operational launch in the calendar year 2029.

• Total Bed Expansion

• The company aims to more than double its current capacity, expanding from 1,048 beds to approximately 2,500 beds upon completion of these projects.

The company has a clear and aggressive expansion pipeline aimed at significantly increasing its scale and market presence in Western India over the next five years.

• Gross Profit Margin: Remained robust and slightly improved to 80.8% in 9MFY26 from 80.5% in 9MFY25.

• EBITDA Margin: Held steady at 22.8% for 9MFY26, consistent with the 22.8% margin in the prior year, demonstrating stable core operational profitability.

• PBT Margin: Contracted to 17.3% in 9MFY26 from 20.4% in 9MFY25. The compression is primarily attributable to the Rs 6.4 crore exceptional item related to the New Labour Code.

• PAT Margin: Declined to 12.9% in 9MFY26 from 15.4% in 9MFY25, reflecting the impact of the exceptional charge on the bottom line.

While core operational margins remain stable, overall profitability margins have faced pressure due to a one-off regulatory cost impact in the current fiscal period.

• Regulatory and Compliance Costs

• The company's profitability was directly impacted by a statutory change related to New Labour Codes, resulting in an exceptional expense of Rs 6.4 crore in Q3FY26.

• This event highlights the tangible risk of regulatory changes on the company's cost structure and bottom line. Future changes in labor laws, healthcare regulations, or other statutory requirements could pose similar risks.

Regulatory changes represent a key risk factor that can introduce unforeseen costs and negatively affect the company's profitability.

• Dombivli Hospital Completion

• The company announced the successful completion of its new hospital in Dombivli ahead of its planned Q1FY27 schedule. The entire construction and fit-out process was completed in just over 24 months, showcasing strong project execution capabilities.

• Financial Data Revision

• The company issued a revised investor presentation to correct a data discrepancy. The EBITDA for Q3FY26 was corrected to Rs 85.4 crore and for 9MFY26 to Rs 249.2 crore in the operational highlights, ensuring accuracy in financial reporting to stakeholders.

• Payor Mix

• The company's revenue stream remains diversified and stable. For 9MFY26, the payor mix was composed of Self-Payors (55.7%), Insurance Companies (43.2%), and Government Schemes (1.1%). This mix is nearly identical to the prior year, indicating a consistent patient base.

Key updates reflect strong project management in expansion activities, a commitment to transparent financial reporting, and a stable revenue base from a diversified payor mix.